Beam Therapeutics Inc.

CMN Weekly (28 August 2026) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (24 Juli 2026) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (26 June 2026) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Clinical: Beam Advances Base Editing For PKU

Beam Therapeutics has received U.S. FDA clearance of its Investigational New Drug (IND) application for BEAM-304, an in vivo base-editing therapy for...

Rival Editors Converge on AATD as Data Mount

Alpha-1 antitrypsin deficiency (AATD) has turned into the most crowded proving ground in genetic medicine, with five editing companies reporting fresh...

CMN Weekly (27 March 2026) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (27 February 2026) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (12 December 2025) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Beam Therapeutics Inc.

Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma, (NCT06934382)
Sponsors:
Stephan Grupp MD PhD, Children's Hospital of Philadelphia

IND Enabling

Phase I

Phase II

Phase III

Glycogen Storage Disease Type Ia, GSDIa, (NCT06735755)
Sponsors:
Beam Therapeutics Inc.

IND Enabling

Phase I

Phase II

Phase III

Alpha 1-Antitrypsin Deficiency, AATD, (NCT06389877)
Sponsors:
Beam Therapeutics Inc.

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Trait, (NCT06071377)
Sponsors:
National Alliance for Sickle Cell Centers

IND Enabling

Phase I

Phase II

Phase III

T-Cell Acute Lymphoblastic Leukaemia, T-ALL, and Lymphoma, T-LL, (NCT05885464)
Sponsors:
Beam Therapeutics Inc.

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT05456880)
Sponsors:
Beam Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Search CRISPR Medicine